Mitchell de Long
Corporate Officer/Principal bei AERIE PHARMACEUTICALS, INC.
Aktive Positionen von Mitchell de Long
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| AERIE PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.01.2005 | - |
Karriereverlauf von Mitchell de Long
Ehemalige bekannte Positionen von Mitchell de Long
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| PROCTER & GAMBLE COMPANY | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Ausbildung von Mitchell de Long
| Stanford University | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 4 |
Operativ
| Doctorate Degree | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
| Corporate Officer/Principal | 1 |
Sektoral
| Consumer Services | 2 |
| Consumer Non-Durables | 2 |
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| PROCTER & GAMBLE COMPANY | Consumer Non-Durables |
| Private Unternehmen | 1 |
|---|---|
Aerie Pharmaceuticals, Inc.
 Aerie Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on January 1, 2005 and is headquartered in Durham, NCForth Worth, TX. | Health Technology |
- Börse
- Insiders
- Mitchell de Long
- Erfahrung